[1] Garon E B, Rizvi N A, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer[J]. The New England Journal of Medicine, 2015, 372(21): 2018-2028.
[2] Reck M, Rodrí guez-Abreu D, Robinson A G, et al. Fiveyear outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score≥50%[J]. Journal of Clinical Oncology, 2021, 39(21): 2339-2349.
[3] Mok T S K, Wu Y L, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial [J]. The Lancet, 2019, 393(10183): 1819-1830.
[4] 付烊, 朱波, 章必成 . 晚期肺癌免疫治疗的现状与未来[J]. 医药导报, 2019, 38(8): 4.
[5] Herrera F G, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice[J]. CA-A Cancer Journal for Clinicians, 2017, 67(1): 65-85.
[6] Socinski M A, Nishio M, Jotte R M, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC[J]. Journal of Thoracic Oncology, 2021, 16(11): 1909-1924.
[7] Naoki F, Satoshi W, Atsushi N, et al. A phase 2 study of atezolizumab (atezo) plus bevacizumab (bev) plus carboplatin (carbo) plus paclitaxel (pac; ABCP) for previously treated patients with NSCLC harboring EGFR mutations (EGFRm) [C]//2022 ASCO Annual Meeting. Chicago, USA: Journal of Clinical Oncology, 2022.
[8] Paz-Ares L, Ciuleanu T E, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer(CheckMate 9LA): An international, randomised, open-label, phase 3 trial[J]. Lancet Oncology, 2021, 22(2): 198-211.
[9] Brahmer J R, Lee J S, Ciuleanu T E, et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in checkmate 227[J]. Journal of Clinical Oncology, 2023, 41(6): 1200-1212.
[10] Goto Y , Su W C, Benjamin P L, et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC) [C]//ASCO Annual Meeting 2023. Chicago, USA: Journal of Clinical Oncology, 2023.
[11] Creelan B C, Wang C, Teer J K, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: A phase 1 trial[J]. Nature Medicine, 2021, 27(8): 1410-1418.
[12] Kim C G, Kim K H, Pyo K H, et al. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer[J]. Annals of Oncology, 2019, 30(7): 1104-1113.
[13] 朱波. 肿瘤免疫治疗耐药机制与克服策略[J]. 中国肿瘤生物治疗杂志, 2023, 30(3): 187-195.
[14] Nie J, Wang C M, Liu Y, et al. Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma[J]. Journal of Clinical Oncology, 2019, 37(17): 1479-1489.
[15] Ribas A, Medina T, Kummar S, et al. SD-101 in combination with pembrolizumab in advanced melanoma: Results of a phaseⅠb, multicenter study[J]. Cancer Discovery, 2018, 8(10): 1250-1257.
[16] Ni K Y, Luo T K, Lan G X, et al. A nanoscale metal-organic framework to mediate photodynamic therapy and deliver CpG oligodeoxynucleotides to enhance antigen presentation and cancer immunotherapy[J]. Angewandte Chemie International Edition, 2020, 59(3): 1108-1112.
[17] Kawashima S, Inozume T, Kawazu M, et al. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment[J]. Journal for Immunotherapy of Cancer, 2021, 9(11): e003134.
[18] Bockorny B, Semenisty V, Macarulla T, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: The COMBAT trial[J]. Nature Medicine, 2020, 26(6): 878-885.
[19] Flores-toro J A, Luo D F, Gopinath A, et al. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas[J]. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117(2): 1129-1138.
[20] Vargas F A, Furnessaj S, Solomon I, et al. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors[J]. Immunity, 2017, 46 (4): 577-586.
[21] Cannarile M A , Weisser M , Jacob W , et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy[J]. Journal for Immunotherapy of Cancer, 2017, 5(1): 53
[22] Mariathasan S, Turley S J, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells[J]. Nature, 2018, 554(7693): 544-548.
[23] Miron B, Geynisman D M. Bempegaldesleukin/nivolumab and challenges in first-line treatment of metastatic urothelial carcinoma[J]. European Urology, 2022, 82(4): 374-376.
[24] Kurz E, Hirsch C A, Dalton T, et al. Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer[J]. Cancer Cell, 2022, 40(7): 720-737.
[25] Davar D, Dzutsev A K, Mcculloch J A, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients[J]. Science, 2021, 371(6529): 595-602.
[26] Vokes N I, Gandara D R, Sezer A, et al. Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab(cemi) vs chemotherapy (chemo)[C]//ASCO Annual Meeting 2023. Chicago, USA: Journal of Clinical Oncology, 2023.
[27] Sánchez-Magraner L, Gumuzio J, Miles J, et al. Functional engagement of the PD-1/PD-L1 complex but not PD-L1 expression is highly predictive of patient response to immunotherapy in non-small-cell lung cancer[J]. Journal of Clinical Oncology, 2023, 41(14): 2561-2570.
[28] Lichtenstein M R L, Nipp R D, Muzikansky A, et al. Impact of age on outcomes with immunotherapy in patients with non-small cell lung cancer[J]. Journal of Thoracic Oncology, 2019, 14(3): 547-552.
[29] Uematsu M, Tsukita Y, Tozuka T, et al. First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057) [C]//ASCO Annual Meeting 2023. Chicago, USA: Journal of Clinical Oncology, 2023.
[30] Yang J C, Lee D H, Lee J S, et al. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study[C]//2023 ASCO Annual Meeting. Chicago, USA: Journal of Clinical Oncology, 2023.
[31] Lee A T M, Nagasaka M. CheckMate-722: The rise and fall of nivolumab with chemotherapy in TKI-refractory EGFR-mutant NSCLC[J]. Lung Cancer (Auckl), 2023, 14: 41-46.
[32] Lu S, Wu L, Jian H, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): First interim results from a randomised, double-blind, multicentre, phase 3 trial[J]. Lancet Oncology, 2022, 23(9): 1167-1179.
[33] Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper[J]. Annals of Oncology, 2016, 27(4): 559-574.
[34] 中国临床肿瘤学会(CSCO)免疫治疗专家委员会 . 免疫检查点抑制剂相关的毒性管理指南[M]. 北京: 人民卫生出版社, 2023.
